796 related articles for article (PubMed ID: 16964403)
21. [Expression of melanoma antigen gene in urinary transitional cell carcinomas].
Geng L; Yu LZ; Du P; Ma M; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 May; 43(10):667-71. PubMed ID: 16008943
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of Ku 70 and Ku 80 mRNA expression in transitional cell carcinomas of the urinary bladder related to tumor progression.
Korabiowska M; Quentin T; Schlott T; Bauer H; Kunze E
World J Urol; 2004 Dec; 22(6):431-40. PubMed ID: 15551138
[TBL] [Abstract][Full Text] [Related]
23. Histogenesis of nonurothelial carcinomas of the urinary bladder from pre-existent transitional cell carcinomas. A histopathological and immunohistochemical study.
Kunze E; Francksen B
Urol Res; 2002 Mar; 30(1):66-78. PubMed ID: 11942328
[TBL] [Abstract][Full Text] [Related]
24. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
25. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
26. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
27. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
28. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
29. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.
Tsuruta H; Kishimoto H; Sasaki T; Horie Y; Natsui M; Shibata Y; Hamada K; Yajima N; Kawahara K; Sasaki M; Tsuchiya N; Enomoto K; Mak TW; Nakano T; Habuchi T; Suzuki A
Cancer Res; 2006 Sep; 66(17):8389-96. PubMed ID: 16951148
[TBL] [Abstract][Full Text] [Related]
30. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
[TBL] [Abstract][Full Text] [Related]
31. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.
Koksal IT; Yasar D; Dirice E; Usta MF; Karauzum S; Luleci G; Baykara M; Sanlioglu S
Urol Int; 2005; 75(2):102-6. PubMed ID: 16123561
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
33. A global profile of gene promoter methylation in treatment-naïve urothelial cancer.
Ibragimova I; Dulaimi E; Slifker MJ; Chen DY; Uzzo RG; Cairns P
Epigenetics; 2014 May; 9(5):760-73. PubMed ID: 24521710
[TBL] [Abstract][Full Text] [Related]
34. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.
Zurita M; Lara PC; del Moral R; Torres B; Linares-Fernández JL; Arrabal SR; Martínez-Galán J; Oliver FJ; Ruiz de Almodóvar JM
BMC Cancer; 2010 May; 10():217. PubMed ID: 20487521
[TBL] [Abstract][Full Text] [Related]
35. [Hypermethylation of syk gene in promoter region is associated with oncogenesis, metastasis of breast carcinoma].
Ding YB; Wu ZY; Wang S; Zha XM; Zheng W; Liu XA; Fan P
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):290-3. PubMed ID: 15059510
[TBL] [Abstract][Full Text] [Related]
36. A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer.
Christoph F; Hinz S; Kempkensteffen C; Weikert S; Krause H; Schostak M; Schrader M; Miller K
J Cancer Res Clin Oncol; 2007 Jun; 133(6):343-9. PubMed ID: 17160380
[TBL] [Abstract][Full Text] [Related]
37. CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer.
Gutiérrez MI; Siraj AK; Khaled H; Koon N; El-Rifai W; Bhatia K
Mod Pathol; 2004 Oct; 17(10):1268-74. PubMed ID: 15154012
[TBL] [Abstract][Full Text] [Related]
38. Hypermethylation leads to silencing of the SYK gene in human breast cancer.
Yuan Y; Mendez R; Sahin A; Dai JL
Cancer Res; 2001 Jul; 61(14):5558-61. PubMed ID: 11454707
[TBL] [Abstract][Full Text] [Related]
39. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
40. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
